Valerie Odegard, Ph.D.

Valerie Odegard, Ph.D., a successful biotechnology executive with more than 15 years of experience in the development of immunotherapies to treat autoimmune/inflammatory disease and cancer, serves as independent director for Abata.  Valerie is currently the Chief Executive Officer of Dovetail Therapeutics and a Venture Partner with OrbiMed Advisors.  Previously, she was President and Chief Scientific Officer of Silverback Therapeutics ($SBTX), a clinical-stage biotechnology company focused on tissue-targeted therapeutics, and before that, Vice President of R&D at Juno Therapeutics, where she was responsible for the development of novel cellular immunotherapies prior to Juno’s acquisition by Celgene.  Valerie held leadership positions at Novo Nordisk and Trubion Pharmaceuticals, where she oversaw the development of therapeutics for oncology and inflammatory conditions.  She received her Ph.D. in Immunobiology from Yale University.